Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Macrophage-Derived IL1β and TNFα Regulate Arginine Metabolism in Neuroblastoma.

Fultang L, Gamble LD, Gneo L, Berry AM, Egan SA, De Bie F, Yogev O, Eden GL, Booth S, Brownhill S, Vardon A, McConville CM, Cheng PN, Norris MD, Etchevers HC, Murray J, Ziegler DS, Chesler L, Schmidt R, Burchill SA, Haber M, De Santo C, Mussai F.

Cancer Res. 2019 Feb 1;79(3):611-624. doi: 10.1158/0008-5472.CAN-18-2139. Epub 2018 Dec 13.

PMID:
30545920
2.

Expression analysis of the MCPH1/BRIT1 and BRCA1 tumor suppressor genes and telomerase splice variants in epithelial ovarian cancer.

Alsiary R, Brownhill SC, Brüning-Richardson A, Hutson R, Griffin N, Morrison EE, Bond J, Burchill SA, Bell SM.

Gene. 2018 Sep 25;672:34-44. doi: 10.1016/j.gene.2018.05.113. Epub 2018 May 31.

PMID:
29860064
3.

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis.

Corrias MV, Parodi S, Tchirkov A, Lammens T, Vicha A, Pasqualini C, Träger C, Yáñez Y, Dallorso S, Varesio L, Luksch R, Laureys G, Valteau-Couanet D, Canete A, Pöetschger U, Ladenstein R, Burchill SA.

Pediatr Blood Cancer. 2018 Jul;65(7):e27052. doi: 10.1002/pbc.27052. Epub 2018 Mar 30.

PMID:
29603574
4.

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.

Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F.

Cancer. 2017 Apr 1;123(7):1095-1105. doi: 10.1002/cncr.30380. Epub 2016 Dec 16. Review.

5.

PCR-based amplification of circulating RNAs as prognostic and predictive biomarkers - Focus on neuroblastoma.

Brownhill SC, Burchill SA.

Pract Lab Med. 2016 Apr 20;7:41-44. doi: 10.1016/j.plabm.2016.04.003. eCollection 2017 Apr.

6.

Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.

Viprey VF, Gregory WM, Corrias MV, Tchirkov A, Swerts K, Vicha A, Dallorso S, Brock P, Luksch R, Valteau-Couanet D, Papadakis V, Laureys G, Pearson AD, Ladenstein R, Burchill SA.

J Clin Oncol. 2014 Apr 1;32(10):1074-83. doi: 10.1200/JCO.2013.53.3604. Epub 2014 Mar 3.

PMID:
24590653
7.

The first European interdisciplinary ewing sarcoma research summit.

Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R.

Front Oncol. 2012 May 29;2:54. doi: 10.3389/fonc.2012.00054. eCollection 2012.

8.

Detection and characterisation of multi-drug resistance protein 1 (MRP-1) in human mitochondria.

Roundhill EA, Burchill SA.

Br J Cancer. 2012 Mar 13;106(6):1224-33. doi: 10.1038/bjc.2012.40. Epub 2012 Feb 21.

9.

Heterogeneous role of the glutathione antioxidant system in modulating the response of ESFT to fenretinide in normoxia and hypoxia.

Magwere T, Burchill SA.

PLoS One. 2011;6(12):e28558. doi: 10.1371/journal.pone.0028558. Epub 2011 Dec 8.

10.

Identification of reference microRNAs and suitability of archived hemopoietic samples for robust microRNA expression profiling.

Viprey VF, Corrias MV, Burchill SA.

Anal Biochem. 2012 Feb 15;421(2):566-72. doi: 10.1016/j.ab.2011.10.022. Epub 2011 Oct 18.

PMID:
22074795
11.

Oxidative stress and therapeutic opportunities: focus on the Ewing's sarcoma family of tumors.

Smith DG, Magwere T, Burchill SA.

Expert Rev Anticancer Ther. 2011 Feb;11(2):229-49. doi: 10.1586/era.10.224. Review.

PMID:
21342042
12.
13.

Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial.

Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslböck M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jürgens H, Kovar H.

J Clin Oncol. 2010 Apr 20;28(12):1982-8. doi: 10.1200/JCO.2009.23.3585. Epub 2010 Mar 22.

PMID:
20308673
14.

Gene expression profiling for discovery of novel markers of minimal disease.

Viprey VF, Burchill SA.

Clin Cancer Res. 2009 Nov 1;15(21):6742; author reply 6743. doi: 10.1158/1078-0432.CCR-09-1601. Epub 2009 Oct 27. No abstract available. Erratum in: Clin Cancer Res. 2010 May 1;16(9):2696. Burchil, Susan A [corrected to Bruchill, Susan A].

15.

p38(MAPK): stress responses from molecular mechanisms to therapeutics.

Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA.

Trends Mol Med. 2009 Aug;15(8):369-79. doi: 10.1016/j.molmed.2009.06.005. Epub 2009 Aug 6. Review.

16.

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.

Beiske K, Burchill SA, Cheung IY, Hiyama E, Seeger RC, Cohn SL, Pearson AD, Matthay KK; International neuroblastoma Risk Group Task Force.

Br J Cancer. 2009 May 19;100(10):1627-37. doi: 10.1038/sj.bjc.6605029. Epub 2009 Apr 28.

17.

The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utility.

Proctor A, Brownhill SC, Burchill SA.

Biochim Biophys Acta. 2009 Apr;1792(4):260-74. doi: 10.1016/j.bbadis.2009.02.011. Epub 2009 Mar 2. Review.

18.

Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.

Dalal S, Burchill SA.

Eur J Cancer. 2009 Mar;45(4):713-22. doi: 10.1016/j.ejca.2008.11.045. Epub 2009 Jan 10.

PMID:
19136249
19.

Molecular abnormalities in Ewing's sarcoma.

Burchill SA.

Expert Rev Anticancer Ther. 2008 Oct;8(10):1675-87. doi: 10.1586/14737140.8.10.1675. Review.

PMID:
18925858
20.

Minimal disease monitoring by QRT-PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials.

Viprey VF, Lastowska MA, Corrias MV, Swerts K, Jackson MS, Burchill SA.

J Pathol. 2008 Oct;216(2):245-52. doi: 10.1002/path.2406.

PMID:
18702176
21.

Manipulation of oxidative stress to induce cell death in Ewing's sarcoma family of tumours.

Magwere T, Myatt SS, Burchill SA.

Eur J Cancer. 2008 Oct;44(15):2276-87. doi: 10.1016/j.ejca.2008.06.008. Epub 2008 Jul 24.

PMID:
18656345
22.

BAY 11-7082 induces cell death through NF-kappaB-independent mechanisms in the Ewing's sarcoma family of tumours.

White DE, Burchill SA.

Cancer Lett. 2008 Sep 18;268(2):212-24. doi: 10.1016/j.canlet.2008.03.045. Epub 2008 May 8.

PMID:
18471963
23.

Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group.

Roberts P, Burchill SA, Brownhill S, Cullinane CJ, Johnston C, Griffiths MJ, McMullan DJ, Bown NP, Morris SP, Lewis IJ.

Genes Chromosomes Cancer. 2008 Mar;47(3):207-20.

PMID:
18064647
25.

Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT.

Brownhill SC, Taylor C, Burchill SA.

Br J Cancer. 2007 Jun 18;96(12):1914-23. Epub 2007 May 29.

26.

Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.

Łastowska M, Viprey V, Santibanez-Koref M, Wappler I, Peters H, Cullinane C, Roberts P, Hall AG, Tweddle DA, Pearson AD, Lewis I, Burchill SA, Jackson MS.

Oncogene. 2007 Nov 22;26(53):7432-44. Epub 2007 May 28.

PMID:
17533364
27.

Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: quality assurance on behalf of SIOPEN-R-NET.

Viprey VF, Corrias MV, Kagedal B, Oltra S, Swerts K, Vicha A, Ladenstein R, Burchill SA.

Eur J Cancer. 2007 Jan;43(2):341-50. Epub 2006 Oct 4.

PMID:
17023157
28.

The hollow fiber assay for drug responsiveness in the Ewing's sarcoma family of tumors.

Bridges EM, Bibby MC, Burchill SA.

J Pediatr. 2006 Jul;149(1):103-11.

PMID:
16860137
29.

What do, can and should we learn from models to evaluate potential anticancer agents?

Burchill SA.

Future Oncol. 2006 Apr;2(2):201-11. Review.

PMID:
16563089
30.

Detecting minimal residual disease in neuroblastoma patients-the present state of the art.

Beiske K, Ambros PF, Burchill SA, Cheung IY, Swerts K.

Cancer Lett. 2005 Oct 18;228(1-2):229-40. Review.

PMID:
15951104
31.

p38MAPK-Dependent sensitivity of Ewing's sarcoma family of tumors to fenretinide-induced cell death.

Myatt SS, Redfern CP, Burchill SA.

Clin Cancer Res. 2005 Apr 15;11(8):3136-48.

32.

Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.

Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, Lewis IJ, Johnston C, Laurence V, Burchill SA.

Clin Cancer Res. 2005 Mar 15;11(6):2364-78.

33.
34.

Efficient infection and persistence of a herpesvirus saimiri-based gene delivery vector into human tumor xenografts and multicellular spheroid cultures.

Smith PG, Burchill SA, Brooke D, Coletta PL, Whitehouse A.

Cancer Gene Ther. 2005 Mar;12(3):248-56.

PMID:
15540115
35.

Basic fibroblast growth factor-induced cell death is effected through sustained activation of p38MAPK and up-regulation of the death receptor p75NTR.

Williamson AJ, Dibling BC, Boyne JR, Selby P, Burchill SA.

J Biol Chem. 2004 Nov 12;279(46):47912-28. Epub 2004 Aug 13.

36.

A systematic review of molecular and biological tumor markers in neuroblastoma.

Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):4-12. Review.

37.

Micrometastases in neuroblastoma: are they clinically important?

Burchill SA.

J Clin Pathol. 2004 Jan;57(1):14-20. Review.

38.
39.

Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future.

Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, Burchill SA.

Br J Cancer. 2003 Apr 22;88(8):1191-8.

40.

A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma.

Riley RD, Burchill SA, Abrams KR, Heney D, Lambert PC, Jones DR, Sutton AJ, Young B, Wailoo AJ, Lewis IJ.

Health Technol Assess. 2003;7(5):1-162. Review. No abstract available.

41.
42.

A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family.

Riley RD, Burchill SA, Abrams KR, Heney D, Sutton AJ, Jones DR, Lambert PC, Young B, Wailoo AJ, Lewis IJ.

Eur J Cancer. 2003 Jan;39(1):19-30. Review.

PMID:
12504654
43.

Myogenin--a more specific target for RT-PCR detection of rhabdomyosarcoma than MyoD1.

Michelagnoli MP, Burchill SA, Cullinane C, Selby PJ, Lewis IJ.

Med Pediatr Oncol. 2003 Jan;40(1):1-8.

PMID:
12426678
44.

Comparison of the RNA-amplification based methods RT-PCR and NASBA for the detection of circulating tumour cells.

Burchill SA, Perebolte L, Johnston C, Top B, Selby P.

Br J Cancer. 2002 Jan 7;86(1):102-9.

45.
46.

Mechanism of basic fibroblast growth factor-induced cell death.

Burchill SA, Westwood G.

Apoptosis. 2002 Feb;7(1):5-12. Review.

PMID:
11773700
47.

Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.

Burchill SA, Kinsey SE, Picton S, Roberts P, Pinkerton CR, Selby P, Lewis IJ.

Med Pediatr Oncol. 2001 Jan;36(1):213-9.

PMID:
11464888
48.

Decreased wild-type full-length Et-A and -B receptors in neuroblastoma and Ewing sarcoma cells.

Berry PA, Zhang YF, Carter ND, Jeffery S, Burchill SA.

Med Pediatr Oncol. 2001 Jan;36(1):142-6.

PMID:
11464869
49.
50.

Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.

Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA.

Cancer Res. 2000 Nov 1;60(21):6160-70.

Supplemental Content

Loading ...
Support Center